环状RNA在乳腺癌中作用的研究进展

doi:10.16352/j.issn.1001-6325.2022.03.007

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (3): 507-511.doi: 10.16352/j.issn.1001-6325.2022.03.007

环状RNA在乳腺癌中作用的研究进展

何啸, 胡为杰, 吕文昌, 任玉萍, 吴敏, 吴毅平, 张奇^*

华中科技大学同济医学院附属同济医院整形美容外科, 湖北武汉 430022

收稿日期:2020-09-15 修回日期:2021-04-06 出版日期:2022-03-05 发布日期:2022-03-04
通讯作者: ^* zhangqi06172@163.com
基金资助:
中国光华科技基金会(2019JZXM001);2020年武汉市科技局应用基础前沿专项(2020020601012241)

Advances on the roles of circular RNA in breast cancer

HE Xiao, HU Wei-jie, LYU Wen-chang, REN Yu-ping, WU Min, WU Yi-ping, ZHANG Qi^*

Department of Plastic Surgery, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430022, China

Received:2020-09-15 Revised:2021-04-06 Online:2022-03-05 Published:2022-03-04
Contact: ^* zhangqi06172@163.com

摘要/Abstract

摘要： 环状RNA(circRNA)是一类具有环状结构且广泛存在的非编码RNA,具有多样性、特异性、保守性和稳定性等特征。作为新兴的非编码调控分子,circRNA主要通过竞争性内源RNA的机制来调控乳腺癌(BC)细胞增殖和转移,并且参与了多种化学药物治疗耐药、影响疗效。阐明circRNA在BC中的功能与机制,将有助于为BC的诊断和治疗提供新颖有效的策略。

关键词: 乳腺癌, 环状RNA, 竞争性内源RNA, 化学治疗耐药

Abstract: Circular RNA (circRNA) is a kind of non-coding RNA with circular structure and is found in a variety of cell types. CircRNA is characterized by diversity, specificity, conservatism and stability. As an emerging non-coding regulatory molecules, circRNA can regulate the proliferation and metastasis of breast cancer (BC) mainly through the mechanism of competitive endogenous RNA, and is involved in a variety of chemotherapy resistance and affect the efficacy. Elucidating the functions and mechanisms of circRNA in BC may provide novel and effective strategies for the diagnosis and treatment of BC.

Key words: breast cancer, circular RNA, competitive endogenous RNA, chemotherapy resistance

中图分类号:

R737.9

何啸, 胡为杰, 吕文昌, 任玉萍, 吴敏, 吴毅平, 张奇. 环状RNA在乳腺癌中作用的研究进展[J]. 基础医学与临床, 2022, 42(3): 507-511.

HE Xiao, HU Wei-jie, LYU Wen-chang, REN Yu-ping, WU Min, WU Yi-ping, ZHANG Qi. Advances on the roles of circular RNA in breast cancer[J]. Basic & Clinical Medicine, 2022, 42(3): 507-511.

参考文献

[1]郑亚男, 李梅, 赵基源. 乳腺癌骨转移分子机制及靶向药物的研究进展[J].基础医学与临床, 2021, 41:433-437.
[2]Narrandes S, Huang SJ, Murphy L, et al. The exploration of contrasting pathways in triple negative breast cancer (TNBC)[J]. BMC Cancer, 2018, 18:22. doi: 10.1186/s12885-017-3939-4.
[3]Hu Q, Zhou T. EIciRNA-mediated gene expression: tunability and bimodality[J]. FEBS Lett, 2018, 592:3460-3471.
[4]Zhang CL, Wu H, Wang YH, et al. Expression patterns of circular RNAs from primary kinase transcripts in the mammary glands of lactating rats[J]. J Breast Cancer, 2015, 18:235-241.
[5]Pagliarini V, Jolly A, Bielli P, et al. Sam68 binds Alu-rich introns in SMN and promotes pre-mRNA circulariza-tion[J]. Nucleic Acids Res, 2020, 48:633-645.
[6]Venø MT, Hansen TB, Venø ST, et al. Spatio-temporal regulation of circular RNA expression during porcine embryonic brain development[J]. Genome Biol, 2015, 16:245. doi: 10.1186/s13059-015-0801-3.
[7]Li Z, Huang C, Bao C, et al. Exon-intron circular RNAs regulate transcription in the nucleus[J]. Nat Struct Mol Biol, 2015, 22:256-264.
[8]Wesselhoeft RA, Kowalski PS, Anderson GD. Engineer-ing circular RNA for potent and stable translation in eukaryotic cells[J]. Nat Commun, 2018, 9:2629. doi: 10.1038/s41467-018-05096-6.
[9]Wang Q, Li Z, Hu Y, et al. Circ-TFCP2L1 promotes the proliferation and migration of triple negative breast cancer through sponging miR-7 by inhibiting PAK1[J]. J Mammary Gland Biol Neoplasia, 2019, 24:323-331.
[10]Kong Y, Yang L, Wei W, et al. CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression[J]. Epigenomics, 2019, 11:1163-1176.
[11]Yang R, Xing L, Zheng X, et al. The circRNA circAGFG1 acts as a sponge of miR-195-5p to promote triple-negative breast cancer progression through regulating CCNE1 expression[J]. Mol Cancer, 2019, 18:4. doi: 10.1186/s12943-018-0933-7.
[12]Zhang J, Xu HD, Xing XJ, et al. CircRNA-069718 promotes cell proliferation and invasion in triple-negative breast cancer by activating Wnt/β-catenin pathway[J]. Eur Rev Med Pharmacol Sci, 2019, 23:5315-5322.
[13]Wang ST, Liu LB, Li XM, et al. Circ-ITCH regulates triple-negative breast cancer progression through the Wnt/β-catenin pathway[J]. Neoplasma, 2019, 66:232-239.
[14]Ren S, Liu J, Feng Y, et al. Knockdown of circDENND4C inhibits glycolysis, migration and invasion by up-regulating miR-200b/c in breast cancer under hypoxia[J]. J Exp Clin Cancer Res, 2019, 38:388. doi: 10.1186/s13046-019-1398-2.
[15]Liang G, Liu Z, Tan L, et al. HIF1α-associated circdennd4c promotes proliferation of breast cancer cells in hypoxic environment[J]. Anticancer Res, 2017, 37:4337-4343.
[16]Zeng K, He B, Yang BB, et al. The pro-metastasis effect of circANKS1B in breast cancer[J]. Mol Cancer, 2018, 17:160. doi: 10.1186/s12943-018-0914-x.
[17]Xu JH, Wang Y, Xu D. Hsa-circ-001569 is an unfavo-rable prognostic factor and promotes cell prolifera-tion and metastasis by modulating PI3K-AKT pathway in breast cancer[J]. Cancer Biomark, 2019, 25:193-201.
[18]Pan G, Mao A, Liu J, et al. Circular RNA hsa_circ_0061825 (circ-TFF1) contributes to breast cancer progression through targeting miR-326/TFF1 signalling[J]. Cell Prolif, 2020, 53:1-14.
[19]Lin X, Hong S, Chen J, et al. The potential targets for metastases: a study on altered circular RNA profile in breast cancer liver metastases[J]. Epigenomics, 2019, 11:1237-1250.
[20]Liang Y, Song X, Li Y, et al. CircKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer[J]. Oncogene, 2019, 38:6850-6866.
[21]Gao D, Zhang X, Liu B, et al. Screening circular RNA related to chemotherapeutic resistance in breast cancer[J]. Epigenomics, 2017, 9:1175-1188.
[22]Liang Y, Song X, Li Y, et al. Targeting the circBMPR2/miR-553/USP4 axis as a potent therapeutic approach for breast cancer[J]. Mol Ther Nucleic Acids, 2019, 17:347-361.
[23]Sang Y, Chen B, Song X, et al. CircRNA_0025202 regulates tamoxifen sensitivity and tumor progression via regulating the miR-182-5p/FOXO3a axis in breast cancer[J]. Mol Ther, 2019, 27:1638-1652.
[24]Uhr K, Sieuwerts AM, de Weerd V, et al. Association of microRNA-7 and its binding partner CDR1-AS with the prognosis and prediction of 1st-line tamoxifen therapy in breast cancer[J]. Sci Rep, 2018, 8:9657. doi: 10.1038/s41598-018-27987-w.
[25]Liu Y, Dong Y, Zhao L, et al. Circular RNA-MTO1 suppresses breast cancer cell viability and reverses monastrol resistance through regulating the TRAF4/Eg5 axis[J]. Int J Oncol, 2018, 53:1752-1762.

环状RNA在乳腺癌中作用的研究进展

Advances on the roles of circular RNA in breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王子辕, 段昭君, 罗云萍. 小鼠乳腺癌肺特异性转移细胞亚系的建立和验证[J]. 基础医学与临床, 2022, 42(7): 1083-1091.
[2]	韩雪莹, 崔丰, 李隽. 乳腺癌缺失因子1(DBC1)影响乳腺癌细胞系对依托泊苷的敏感性[J]. 基础医学与临床, 2022, 42(7): 1060-1066.
[3]	康有力, 赵丹, 杜文静, 李莉. SIRT5通过调控ALDH5A1的琥珀酰化促进人乳腺癌细胞的增殖[J]. 基础医学与临床, 2022, 42(7): 1099-1107.
[4]	谢利华, 杨奇, 李雅倩, 谢心悦, 雷诗娟, 周琳. 转录因子Kaiso下调人乳腺癌细胞系中lncRNA MEG3的表达[J]. 基础医学与临床, 2022, 42(5): 758-762.
[5]	冯天瑞, 严维刚. 环状RNAs在前列腺癌中的研究进展[J]. 基础医学与临床, 2022, 42(1): 179-183.
[6]	王海燕黄明全潘广锐汪贵林梁斌权毅. 低氧微环境促进人乳腺癌细胞系MCF-7的侵袭和增殖[J]. 基础医学与临床, 2021, 41(4): 539-544.
[7]	郑亚男李梅赵基源. 乳腺癌骨转移分子机制及靶向药物的研究进展[J]. 基础医学与临床, 2021, 41(3): 433-437.
[8]	阳德全李常有崔军威韦伟王少平. hsa-miR-4483促进人乳腺癌细胞系的增殖和迁移[J]. 基础医学与临床, 2020, 40(9): 1230-1236.
[9]	胡庆庆鲁兖. 吲哚胺2,3–双加氧酶1抑制剂Epacadostat联合γ干扰素诱导三阴乳腺癌细胞系凋亡[J]. 基础医学与临床, 2020, 40(5): 615-620.
[10]	刘杨朱悦姚景昊刘静周争光赵福友杨燕. 化疗对乳腺癌患者甲状腺功能或结构的影响[J]. 基础医学与临床, 2020, 40(5): 688-691.
[11]	秦岭邢泽宇刘嘉琦钱天一王畅畅王昕王翔. 50例中国男性乳腺癌临床特征和遗传学病因[J]. 基础医学与临床, 2020, 40(5): 684-687.
[12]	刘彦立. 布托啡诺调控PBX3基因抑制乳腺癌细胞系MCF7增殖、迁移和侵袭[J]. 基础医学与临床, 2020, 40(2): 203-208.
[13]	陈桦李静赵春华. miR-210参与调控间充质干细胞向肿瘤相关成纤维细胞转化[J]. 基础医学与临床, 2018, 38(6): 780-786.
[14]	赵丽华位嘉槐英丽张晓敬张超林秋兰王克杰闫红燕郭家良李秋颖. 乳腺癌组织中JARID1B/KDM5B的表达与血液循环肿瘤细胞相关性[J]. 基础医学与临床, 2018, 38(4): 512-515.
[15]	杨振丽徐雅丽卞晓翠冯海凉刘玉琴孙强. 乳腺癌组织细胞的高效原代培养及其特性[J]. 基础医学与临床, 2017, 37(2): 224-229.